Search Results for "Dcis Recurrence After Mastectomy"

10:41 EDT 21st April 2015 | BioPortfolio

Matching Channels

Tumor recurrence

Oncotrace

For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual ...

WolffParkinsonWhite WPW syndrome

Wolff–Parkinson–White syndrome (WPW) is a syndrome of pre-excitation of ventricles of the heart due to an accessory pathway known as the bundle of Kent. This accessory pathway is an abno...

UroGenRA - Genitourinary cancer array

UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It...

Tumor markers

Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in t...

Matching News

I Have DCIS, Should I Have a Bilateral Mastectomy?

By ROBERT McNutt, MD Benefit: There is none. No women with DCIS have been included in a randomized controlled trial. Harm: Cosmetic outcomes are unclear; Second operations to fix the cosmetic outcome ...

20 Years Later, Radiation Protects Against DCIS Recurrence

Rates of recurrence of ductal carcinoma in situ (DCIS) after breast-conserving surgery (BCS) remain lower 20 years after radiotherapy, according to results from the SweDCIS Trial. Reuters Health Inf...

Multigene test can predict risk of disease recurrence for women with ductal carcinoma in situ

In a press conference at SABCS 2014, Prof Rakovitch discusses the use of a multigene test called Oncotype DX DCIS Score (DCIS Score) as a predictor of risk of disease recurrence for patients with d...

Recurrence risk could be predicted by a multigene test in ductal carcinoma breast cancer

Prof Rakovitch talks to ecancertv at SABCS 2014 about the use of a multigene test called Oncotype DX DCIS Score (DCIS Score) which seeks to predict of risk of disease recurrence for patients with duct...

DCIS Test Identifies Patients With Low Recurrence Risk

A new Oncotype test identifies patients with ductal carcinoma in situ (DCIS) who are at low risk for recurrence and for the development of invasive breast cancer. Medscape Medical News

Top stories in health and medicine, December 17, 2014

From MedPage Today: Gene Test Has Promise for Nailing DCIS Recurrence Risk. A multigene panel predicted recurrence risk in ductal carcinoma in situ (DCIS), according to a population-based study. Docs...

SABCS 2014: Multigene test can predict risk of disease recurrence for women with ductal carcinoma in situ

A multigene test called Oncotype DX DCIS Score (DCIS Score) was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in ...

New trial uses breast MRI and genomics for treatment decision-making in DCIS

(ECOG-ACRIN Cancer Research Group) Women with DCIS receive same treatments as those with early-stage invasive cancer. Decisions about lumpectomy/mastectomy often based on mammography alone. Trial exam...

Matching PubMed Articles

The current clinical value of the DCIS Score.

The management of ductal carcinoma in situ (DCIS) can be controversial. Widespread adoption of mammographic screening has made DCIS a more frequent diagnosis, and increasingly smaller, lower-grade les...

Factors Affecting Informed Decision-Making in Women with Increased Breast Cancer Risk or DCIS Pursuing Contralateral Prophylactic Mastectomy.

Despite lack of survival benefit, an increasing number of women diagnosed with ductal carcinoma in situ (DCIS) opt for removal of the unaffected breast in addition to the breast with known pathology, ...

Chest wall recurrence location and the lower-bound target of preventive radiotherapy after transverse incision in modified radical mastectomy.

We investigated the relationship between the lower-bound target of preventive radiation to the chest wall after modified radical mastectomy with a transverse incision and preoperative breast carcinoma...

Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.

Although ductal carcinoma in situ (DCIS) precedes invasive ductal carcinoma (IDC), the related genomic alterations remain unknown. To identify the genomic landscape of DCIS and better understand the m...

Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis.

The introduction of mammographic screening has considerably increased the detection rate of ductal carcinoma in situ (DCIS), which has a high probability of recurrence. We carried out a meta-analysis ...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement